These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22154153)

  • 1. Trastuzumab treatment in multiple lines: current data and future directions.
    Pegram M; Liao J
    Clin Breast Cancer; 2012 Feb; 12(1):10-8. PubMed ID: 22154153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Onkologie; 2005 Nov; 28(11):582-6. PubMed ID: 16249644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.
    Campiglio M; Bufalino R; Sandri M; Ferri E; Aiello RA; De Matteis A; Mottolese M; De Placido S; Querzoli P; Jirillo A; Bottini A; Fantini M; Bonetti A; Pedani F; Mauri M; Molino A; Ferro A; Pupa SM; Sasso M; Ménard S; Balsari A; Tagliabue E
    Breast Cancer Res Treat; 2011 Jul; 128(1):147-54. PubMed ID: 21479926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
    von Minckwitz G; Schwedler K; Schmidt M; Barinoff J; Mundhenke C; Cufer T; Maartense E; de Jongh FE; Baumann KH; Bischoff J; Harbeck N; Lück HJ; Maass N; Zielinski C; Andersson M; Stein RC; Nekljudova V; Loibl S;
    Eur J Cancer; 2011 Oct; 47(15):2273-81. PubMed ID: 21741829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
    Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
    Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
    J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?
    Esposito A; Munzone E; Bagnardi V; Adamoli L; Sciandivasci A; Cullurà D; Goldhirsch A; Nolè F
    Anticancer Drugs; 2012 Nov; 23(10):1089-98. PubMed ID: 22760210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
    García-Sáenz JA; Martín M; Puente J; López-Tarruella S; Casado A; Moreno F; Grande E; Díaz-Rubio E
    Clin Breast Cancer; 2005 Oct; 6(4):325-9. PubMed ID: 16277882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of Herceptin(trastuzumab).
    Baselga J
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S18-24. PubMed ID: 11167087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care.
    Brufsky A
    Am J Clin Oncol; 2010 Apr; 33(2):186-95. PubMed ID: 19675448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
    Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
    J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
    Kulkarni S; Hicks DG
    Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.